Glycoforms of CA125 antigen as a possible cancer marker
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
CA125, a coelomic epithelium-related antigen, is expressed in both normal and pathological conditions. In this study, we compared the glycosylation of CA125 antigen from amniotic fluid and the ovarian carcinoma cell line OVCAR-3, in order to detect possible differences as a specific marker of their origin. Antigens from both sources were radiolabelled and subsequently subjected to the affinity chromatography, using plant lectins differing in carbohydrate specificity as ligands. A common chromatographic scheme was applied to all columns, i.e. they were eluted with: a) washing buffer to wash out non-bound and low-affinity bound fractions, b) a solution of inhibitory sugar and c) a low pH buffer, to release the high affinity bound fractions. CA125 antigen from each source was found to be heterogeneous in respect to the existence of multiple glycoforms, with O-linked glycan chains predominating. However, the binding patterns of both N- and O-linked glycan-reactive lectins indicated distinct differences in carbohydrate composition between CA125 antigen isolated from amniotic fluid and OVCAR-3 cell line. The observed specificites of CA125-oligosaccharide chains might be of special importance from the biomedical aspect, in terms of their possible use for clinical evaluation of gynecological functions in health and disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961 · cited 1×
“The purity of isolated CA125 antigen was checked by SDS-PAGE on 6% separating gel with 3% stacking gel under denaturating and reducing conditions [17].”
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
GREENWOOD, F., HUNTER, W., & GLOVER, J. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,152
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Aberrant Glycosylation In Tumors And Tumor-Associated Carbohydrate Antigens
(1989) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60215-8 · Cited by 1,087 · cited 2×
“Growth and differentiation-dependent appearance of distinct carbohydrate epitopes containing these sugars is known to be typical for both normal and pathological conditions, including embryonic development and gynecological malignancies [14, 28,29].”
Glycoprotein glycosylation and cancer progression
Dennis, J. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00167-1 · Cited by 652 · cited 2×
“Growth and differentiation-dependent appearance of distinct carbohydrate epitopes containing these sugars is known to be typical for both normal and pathological conditions, including embryonic development and gynecological malignancies [14, 28,29].”
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Osawa, T., & Tsuji, T. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.000321 · Cited by 358 · cited 3×
“RCA exhibits specificity towards βGal residues with a preference for β1,4 linked terminal sugars [Galβ1-4GlcNAc], while β1,3 linkages are bound much more weakly [23–25].”
Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
Yancik, R. (2010) · Cancer · doi:10.1002/cncr.2820710205 · Cited by 309 · cited 2×
“Although the use of a panel of different tumor markers seems to be very promising for increasing the sensitivity and specificity of ovarian cancer detection and elimination of many false positive results, there is still a need for more spe-cific markers [9,12,13].”
The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences
O’Brien, T. J., Beard, J. B., Underwood, L. J., Dennis, R. A., Santin, A. D., & York, L. (2001) · Tumor Biology · doi:10.1159/000050638 · Cited by 300
Fractionation of L-fucose-containing oligosaccharides on immobilized Aleuria aurantia lectin.
Yamashita, K., Kochibe, N., Ohkura, T., Ueda, I., & Kobata, A. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89125-6 · Cited by 252
Cited by
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“The subset of cancer-derived molecules (e.g., CA125, Sialyl-Tn and CA19-9) that survive such clearance then become useful markers of disease progression (948) (949) (950) (951) .”
BackgroundMUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
“Attempts to identify diseasespecific MUC16 glycoforms by glycomic analysis are producing interesting results that may enhance the diagnostic potential of this mucin [81-88].”
BackgroundSweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation
Drake, P. M., Cho, W., Li, B., Prakobphol, A., Johansen, E., Anderson, N. L., Regnier, F. E., Gibson, B. W., & Fisher, S. J. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.136333 · Cited by 302
“All of these diagnostic markers are glycoproteins, and the glycans that they present change during oncogenesis (18, 23, 24).”
Molecular Biomarkers for the Early Detection of Ovarian Cancer
Zhang, R., Siu, M. K. Y., Ngan, H. Y. S., & Chan, K. K. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912041 · Cited by 283
“The carbohydrate side chains of glycoproteins can be truncated or aberrant in tumor tissue due to different glycosylation processes that occur during the oncogenic transformation [30].”
BackgroundAberrant glycosylation associated with enzymes as cancer biomarkers
Meany, D. L., & Chan, D. W. (2011) · Clinical Proteomics · doi:10.1186/1559-0275-8-7 · Cited by 247
MUC16 as a novel target for cancer therapy
Aithal, A., Rauth, S., Kshirsagar, P., Shah, A., Lakshmanan, I., Junker, W. M., Jain, M., Ponnusamy, M. P., & Batra, S. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1498845 · Cited by 231
Glycosylation markers in cancer
(2019) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2018.12.005 · Cited by 200
N-linked Glycan Structures and Their Expressions Change in the Blood Sera of Ovarian Cancer Patients
Alley, W. R., Vasseur, J. A., Goetz, J. A., Svoboda, M., Mann, B. F., Matei, D. E., Menning, N., Hussein, A., Mechref, Y., & Novotny, M. V. (2012) · Journal of Proteome Research · doi:10.1021/pr201070k · Cited by 192
Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives
Chia, J., Goh, G. Y. L., & Bard, F. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.03.008 · Cited by 161
Abbott, K. L., Lim, J., Wells, L., Benigno, B. B., McDonald, J. F., & Pierce, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200900537 · Cited by 120
“compared the glycans of CA-125 isolated from amniotic fluid to CA-125 from the OVCAR3 ovarian cancer cell line and found a significant increase in the reactivity of OVCAR3 CA-125 with the lectin E-PHA compared with CA-125 from amniotic fluid [51].”
BackgroundMicroarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer
Chen, K., Gentry‐Maharaj, A., Burnell, M., Steentoft, C., Marcos-Silva, L., Mandel, U., Jacobs, I. J., Dawnay, A., Menon, U., & Blixt, O. (2013) · Journal of Proteome Research · doi:10.1021/pr3010474 · Cited by 112
High-Throughput Glycomic Methods
Trbojević‐Akmačić, I., Lageveen‐Kammeijer, G. S. M., Heijs, B., Pribić, T., Deriš, H., Wuhrer, M., & Lauc, G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01031 · Cited by 120
Modulation of Glycan Recognition by Clustered Saccharide Patches
(2014) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-800097-7.00003-8 · Cited by 84
The sweet and sour of serological glycoprotein tumor biomarker quantification
Kuzmanov, U., Kosanam, H., & Diamandis, E. P. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-31 · Cited by 86
Recent advances in mass spectrometry (MS)-based glycoproteomics in complex biological samples
Chen, Z., Huang, J., & Li, L. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.10.009 · Cited by 85
Kuzmanov, U., Jiang, N., Smith, C. R., Soosaipillai, A. R., & Diamandis, E. P. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800516-mcp200 · Cited by 74
“Another study distinguished the CA125 from OVCAR3 cells and amniotic fluid by multiple lectin chromatography, showing differential binding patterns to a panel of lectins, of the protein from the two different sources (13).”
BackgroundInfluentialLectin approaches for glycoproteomics in FDA-approved cancer biomarkers
Badr, H. A., AlSadek, D. M. M., Darwish, A., ElSayed, A. I., Bekmanov, B., Khussainova, E., Zhang, X., Cho, W. C. S., Djansugurova, L., & Li, C.-Z. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.897611 · Cited by 72
“Additionally, mutations in a number of glycosyltransferase families that are involved in the synthesis and elongation of O-glycan cores can simultaneously generate incomplete glycans, allowing the persistent antigens known as Thomsen-Friedenreich antigen (T or TF, Galb1!3GalNAca-O-Ser/Thr, unsialylated core 1) and Tho…”
BackgroundIntegrated Microfluidic Lectin Barcode Platform for High-Performance Focused Glycomic Profiling
Shang, Y., Zeng, Y., & Zeng, Y. (2016) · Scientific Reports · doi:10.1038/srep20297 · Cited by 57
Shukla, H. D., Vaitiekunas, P., & Cotter, R. J. (2012) · PROTEOMICS · doi:10.1002/pmic.201100519 · Cited by 65
“Recently, the comprehensive proteomic analysis of four ovarian cancer cell lines HTB-75, TOV-112D, TOV-21G, and RMUG-S have shown the presence of CA125, HE4, and KLK6 (where KLK is kallikrein) as promising biomarker (Table 1) [45].”
BackgroundShukla, H. D. (2017) · Proteomes · doi:10.3390/proteomes5040028 · Cited by 43
“In ovarian cancer, many membrane proteins have been found to be aberrantly glycosylated and modified, including CA125 and KLK6, which qualify as potential biomarkers for an early diagnosis [90].”
BackgroundComputational Biology and Chemistry
Behzadi, P., & Bernabò, N. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83539 · Cited by 40
Mucin-Type O-GalNAc Glycosylation in Health and Disease
Bagdonaite, I., Pallesen, E. M. H., Nielsen, M. I., Bennett, E., & Wandall, H. H. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-70115-4_2 · Cited by 45
Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
Weiland, F., Martin, K., Oehler, M. K., & Hoffmann, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130810568 · Cited by 36
“the prefractionation of CA125 include immuno-precipitation, affinity chromatography or a combination of these methods that are associated with similar disadvantages [12,16,28,48,50].”
BackgroundYamamoto, S., Kinoshita, M., & Suzuki, S. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.07.015 · Cited by 40
Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids
Kuzmanov, U., Musrap, N., Kosanam, H., Smith, C. R., Batruch, I., Dimitromanolakis, A., & Diamandis, E. P. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0642 · Cited by 34
CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer
Zhang, H., Zhang, J., Wang, Z., Lü, D., Feng, J., Yang, D., Chen, X., & Yan, X. (2013) · Oncology Letters · doi:10.3892/ol.2013.1147 · Cited by 30
Mu, W., Wu, C., Wu, F., Gao, H., Ren, X., Feng, J., Miao, M., Zhang, H., Chang, D., & Pan, H. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116080 · Cited by 29
Glycans as Biomarkers: Status and Perspectives
Janković, M. (2011) · Journal of Medical Biochemistry · doi:10.2478/v10011-011-0023-5 · Cited by 36
Gao, H., Chen, Y., Zuo, D., Xiao, M., Li, Y., Guo, H. B., Zhang, N., & Chen, R. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0010 · Cited by 28
Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16
Bouanène, H., & Miled, A. (2010) · Disease Markers · doi:10.1155/2010/918457 · Cited by 31
Wang, Y., Ren, S., Jiang, W., Lu, J., Zhang, X., Li, X., Cao, R., & Xu, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8053 · Cited by 25
“Additionally, CA125, the predominant mucin secreted by ovarian cancer was reported to carry Tn antigen in large amounts (25,36).”
BackgroundMitić, N., Milutinovic, B. S., & Janković, M. (2012) · Disease Markers · doi:10.1155/2012/309203 · Cited by 25
Self-citationKuzmanov, U., Smith, C. R., Batruch, I., Soosaipillai, A. R., Diamandis, A., & Diamandis, E. P. (2012) · PROTEOMICS · doi:10.1002/pmic.201100371 · Cited by 24
Qi, Y., Ward, D. G., Pang, C., Wang, Q., Wei, W., Ma, J., Zhang, J., Lou, Q., Shimwell, N. J., Martin, A., et al. (2013) · PROTEOMICS · doi:10.1002/pmic.201300226 · Cited by 21
“As such, many biomarkers currently used for cancer diagnosis are glycoproteins, including AFP [18], AFP-L3 [7], GP73 [19], and DCP [8] in HCC; Her2/neu in breast cancer [20]; PSA in prostate cancer [12]; CA-125 in ovarian cancer [21], and CEA in colorectal, breast, pancreatic, and lung cancer [13].”
BackgroundIntegrins are enriched on aberrantly fucosylated tumour‐derived urinary extracellular vesicles
Islam, M. K., Dhondt, B., Syed, P., Khan, M., Gidwani, K., Webber, J. P., Hendrix, A., Jenster, G. W., Lamminen, T., Boström, P. J., et al. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.64 · Cited by 20
Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood
Maramotti, S., Paci, M., Miccichè, F., Ciarrocchi, A., Cavazza, A., Bortoli, M. D., Vaghi, E., Formisano, D., Canovi, L., Sgarbi, G., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.018 · Cited by 18
Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer
Bhat, S. A., Mir, M. R., Majid, S., Hassan, T., Rehman, M. U., & Kuchy, S. (2018) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2018.03.002 · Cited by 17
Lang, R. E., Rolny, V., Leinenbach, A., Karl, J., Lange, M. S.-D., Kobold, U., Schrader, M. G., Krause, H., Mueller, M., & Vogeser, M. (2019) · Tumor Biology · doi:10.1177/1010428319827223 · Cited by 16
Capitalizing glycomic changes for improved biomarker-based cancer diagnostics
Silva, M. L. S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00140 · Cited by 18
Nano-sized CA125 antigen glycocamouflage: Mucin - Extracellular vesicles alliance to watch?
Mitić, N., Kosanović, M., Milutinovic, B. S., Goč, S., Mladenović, D., Grubiša, I., & Janković, M. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.06.017 · Cited by 10
Self-citationMuthu, M., Chun, S. C., Gopal, J., Anthonydhason, V., Haga, S. W., Devadoss, A. J. P., & Oh, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249336 · Cited by 11
“Chromogranin A (CgA) [25] is a biomarker for neuroendocrine tumors and biomarkers MUC16 (CA-125) [26] and HE4 [27] for ovarian cancer.”
BackgroundGlycans as a Target in the Detection of Reproductive Tract Cancers
Janković, M., Kosanović, M., & Milutinovic, B. S. (2008) · Journal of Medical Biochemistry · doi:10.2478/v10011-007-0041-5 · Cited by 6
Self-citationBouanène, H., Saibi, W., Mokni, M., Sriha, B., Fatma, L. B., Limem, H. B., Ahmed, S. B., Gargouri, A. F., & Miled, A. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9448-x · Cited by 4
Systems Glycobiology: Past, Present, and Future
Yıldız, S. Y. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92267 · Cited by 3
Status Quo of Glycosylation in Cancer: What Is, What Is Not and What Is to Be
Muthu, M., Gopal, J., Chun, S. C., Devadoss, A. J. P., & Oh, J. (2020) · Applied Sciences · doi:10.3390/app10238401 · Cited by 2
“29) [114] and plasminogen activator inhibitor (PAI-1) [115], beta-human chorionic gonadotropin (Beta-hCG) [116], the biomarker of breast cancer; AFP; biomarkers of colorectal cancer [117], biomarkers of liver cancer and germ cell cancer, chromogranin A (CgA) [118], biomarkers of neuroendocrine cancer and MUC16 (CA-125…”
BackgroundDifferences in the Molecular Species of CA125 Across the Phases of the Menstrual Cycle
McLemore, M. R., Miaskowski, C. A., Lee, K. A., Chen, L.-M., & Aouizerat, B. E. (2015) · Biological Research For Nursing · doi:10.1177/1099800414565879 · Cited by 2
“…criteria continue to be valuable for current molecular speciation studies (Andersch-Bjorkman, Thomsson, HolmenLarsson, Ekerhovd, & Hansson, 2007; Bouanène et al., 2012; Jankovic & Milutinovic, 2008; Jankovic & Tapuskovic, 2005; Nustad, Onsrud, Jansson, & Warren, 1998; Saldova et al., 2013).”
BackgroundInfluentialFocused Glycomic Profiling With an Integrated Microfluidic Lectin Barcode System
Shang, Y., & Zeng, Y. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.06.013 · Cited by 3
Activity profile of the CA125 antigen towards human red blood cells
Mitić, N., & Janković, M. (2010) · Archives of Biological Sciences · doi:10.2298/abs1002271m · Cited by 2
“Previous studies on pregnancy-associated CA125 antigens and CA125 antigen from an ovarian carcinoma cell line indicated distinct structural differences in both protein and glycan moieties (Janković and Tapusković, 2005; Janković and Milutinović, 2007, 2008).”
BackgroundAlkhalaf, A. K., Alkhareeb, S. A., Alshammari, B. M., Alharbi, D. A., & Alangari, A. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15008 · Cited by 2
CA-125 of fetal origin can act as a ligand for dendritic cell-specific ICAM-3-grabbing non-integrin
Mitić, N., Milutinovic, B. S., & Janković, M. (2014) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-014-0194-4 · Cited by 2
Self-citationJanković, M., & Mitić, N. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130810387 · Cited by 1
Programmable bio-nano-chip immunosensor for multiplexed detection of ovarian cancer biomarkers
Raamanathan, A. (2011) · Texas ScholarWorks (Texas Digital Library)
MUC16/CA125:: A Candidate Tumor Marker for Diagnosis and Therapy in Ovarian Cancer
Bouanène, H., & Chibani, J. B. (2015) · CRC Press eBooks · doi:10.1201/b18015-17
Mitić, N., Milutinovic, B. S., & Janković, M. (2017) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1610-32
Self-citationProtein Biomarkers for Detecting Cancer
Fisher, S. J., & Witkowska, H. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00022-6
Gbormittah, F. O. (2014) · Digital Repository Service (Northeastern University) · doi:10.17760/d20005087
Metadata
- Authors
- Jankovic, M. M., & Milutinovic, B. S.
- Affiliations
- Institute for the Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080 Zemun, Serbia
- University of Belgrade (RS)
- Venue
- Cancer Biomarkers
- Publisher
- SAGE Publications
- Published
- 2008-02-18
- Volume
- 4
- Issue
- 1
- Pages
- 35-42
- ISSN
- 1574-0153 (ISSN-L)
- 1875-8592
- OpenAlex
- W2100457036
- Cited by
- 59
- References
- 25
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 4 · 2012: 8
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Biomarkers (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- glycoforms, glycosylation, ovarian carcinoma, amniotic fluid, tumor markers, plant lectins, affinity chromatography, gynecological diseases
- MeSH terms
- Chromatography, Affinity, Humans, Biomarkers, Tumor, Wheat Germ Agglutinins, CA-125 Antigen, Plant Lectins, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.